Virios Therapeutics, a cutting-edge biotechnology company with its headquarters in San Diego, California, has been making great strides towards advancing the treatment of chronic diseases such as fibromyalgia with their patented combination antiviral therapies. Recently, Greg Duncan, Chairman and CEO of Virios Therapeutics (NASDAQ: VIRI) and a top executive in the biotech sector, was featured on Global Market Bulletin TV for an exclusive interview discussing his work at the company and their mission to create groundbreaking treatments.
Mr. Duncan stressed the importance of the end-of-Phase 2 meeting request with the U.S Food and Drug Administration (FDA) to progress IMC-1 into Phase 3 development as a treatment for Fibromyalgia that is scheduled for mid March 2023. Furthermore, he informed viewers about Virio’s partnership with Intervene Immune’s for enrollment in exploratory Long COVID trial initiatives aimed at managing symptoms related to post-Acute Sequelae of COVID-19 (PASC).
Greg Duncan boasts an impressive career in biotechnology that includes past roles as President and Chief Executive Officer at Celtaxsys Inc., an anti-inflammatory treatments development firm; various executive level positions within Pfizer; Chairmanship of Biotie Therapeutics; and many more industry roles. His expertise allowed him to lead teams responsible for highly successful launches of multiple pharmaceutical products such as Lipitor, Zoloft, Celebrex, Aricept – to name just a few – marking him out as a leader in drug development organizations. Mr. Duncan holds an MBA from Emory University in Atlanta and undergraduate degree in Economics from State University of New York in Albany.
Virios Therapeutics focuses primarily on developing novel antiviral treatments with their leading experimental prospect being IMC-1 – patented fusion between famciclovir and celecoxib designed to inhibit infection by herpes viruses related to chronic illness like FM – which has been given fast track status by the FDA. In addition, the company is expanding its research into developing IMC-2 (valacyclovir and celecoxib) as a potential treatment for addressing fatigue, sleeplessness, attention deficits, pain, autonomic dysfunction and anxiety presented by Long-COVID or PASC.
If you’re looking for more information about Virios Therapeutics’ cutting edge breakthroughs or would like to learn more about Chairman & CEO Greg Duncan’s stellar career make sure to visit the official website at https://www.virios.com/
